Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kottil Rammohan

Neurology Miami, FL Medical Doctor

NPI 1619051018 CMS profile 164254

1150 Nw 14Th St, Suite 609, Miami, FL 33136

Open in the dashboard

General payments

$175,730

270 records reported · program years 2019–2025

Research payments

$21,988

Paid to them · 6 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$4,787,519 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Kottil Rammohan of Miami, FL is reported in the CMS Open Payments database as having received $175,730 across 270 general payments and $21,988 in research payments paid to them. Separately, studies naming them as principal investigator received $4,787,519 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,363 14
2024 General $5,378 20
2024 Research $1,997 3
2023 General $33,148 44
2023 Research $11,191 1
2022 General $21,201 32
2021 General $40,859 62
2021 Research $8,800 2
2020 General $21,184 28
2019 General $43,597 70

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kottil Rammohan
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Kottil Rammohan were reported at $10,363. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Kottil Rammohan Neurology median Middle half National median
2019 $43,597 $474 $118–$2,177 $163
2020 $21,184 $367 $82–$2,309 $114
2021 $40,859 $438 $104–$2,547 $132
2022 $21,201 $442 $103–$2,388 $149
2023 $33,148 $464 $119–$2,312 $160
2024 $5,378 $468 $119–$2,323 $164
2025 $10,363 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. EMD Serono, Inc. $63,987 89 payments
  2. Genentech USA, Inc. $23,079 21 payments
  3. Novartis Pharmaceuticals Corporation $20,262 40 payments
  4. TG Therapeutics, Inc. $10,489 8 payments
  5. Alexion Pharmaceuticals, Inc. $10,274 17 payments
  6. Biogen, Inc. $9,420 25 payments
  7. Genentech, Inc. $7,472 8 payments
  8. Horizon Therapeutics plc $7,424 14 payments
  9. Merck KGaA $6,880 3 payments
  10. Genzyme Corporation $6,781 15 payments
  11. Other $9,661 30 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $78,183 25 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $52,213 17 payments
  3. Food and Beverage $12,700 188 payments
  4. Education $12,104 12 payments
  5. Travel and Lodging $11,793 23 payments
  6. Honoraria $6,000 1 payment
  7. Compensation for serving as faculty or as a speaker for a medical education program $2,558 2 payments
  8. Gift $180 2 payments
Products named General payments · program years 2019–2025
  1. OCREVUS $27,847 20 payments
  2. KESIMPTA $9,926 19 payments
  3. UPLIZNA $7,424 14 payments
  4. Evobrutinib $6,900 1 payment
  5. Mavenclad Neurology $5,566 11 payments
  6. Non-Covered Product $5,378 5 payments
  7. MAYZENT $5,140 11 payments
  8. Soliris $4,730 9 payments
  9. ARZERRA $1,410 1 payment
  10. Mavenclad Neurology $484 8 payments
  11. Other $3,540 56 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $19,891 2 payments
  2. F. Hoffmann-La Roche AG $1,997 3 payments
  3. Genzyme Corporation $100 1 payment

Records

276 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record